KRAS-mutant cancers: Potential target could overcome treatment resistance

Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is ...
European Medical Journal

Recurrent and Aggressive Solitary Plexiform Neurofibroma with KRAS and AKT1 Alterations: A Case Report

Plexiform neurofibromas (PNF) are benign, often infiltrative tumours of the peripheral nerve sheath classically linked to ...
Frontiers

Progress in genetic mechanisms and precise treatment of neurocutaneous syndrome-related epilepsy

Neurocutaneous syndromes are a group of genetic disorders involving the nervous and cutaneous systems, including Tuberous Sclerosis Complex (TSC), neurofibromatosis type 1 (NF1), and Sturge–Weber ...
ascopubs.org

Proteotranscriptomic Analyses of Microsatellite-Stable Early-Onset Colorectal Cancer

Phase II Study of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and Fluorouracil in Locally Advanced Pancreatic Carcinoma: BTCRC-GI15-067 The prevalence and death rates of ...
ascopubs.org

Evaluating activation of MAPK signaling as a potential mechanism of acquired resistance to lorlatinib in ALK-rearranged lung cancer.

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab ...
eLife

Shc1 cooperates with Frs2 and Shp2 to recruit Grb2 in FGF-induced lens development

This fundamental article significantly advances our understanding of FGF signalling, and in particular, highlights the complex modifications affecting this pathway. The evidence for the authors' ...
Nasdaq

Erasca, Inc. Reports Promising Preclinical Data on ERAS-0015 and ERAS-4001 Targeting RAS/MAPK Pathway at AACR Annual Meeting

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Morningstar

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...